Newsfile Corp
02 Sept 2026, 00:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
A class action lawsuit alleges that Aardvark Therapeutics made materially false statements regarding the safety and prospects of its drug candidate ARD-101. — Allegations of safety issues and overstated clinical prospects for a primary drug candidate typically trigger significant sell-offs in biotech equities.
-0.60The Rosen Law Firm is soliciting lead plaintiffs for a securities class action against Aardvark Therapeutics with a court deadline of October 13, 2026. — The formal organization of a class action increases the likelihood of legal expenses and potential settlement payouts for the company.
-0.20Which stocks this story touches
The company is facing a class action lawsuit alleging materially false and misleading statements regarding the safety and prospects of its drug ARD-101.
Continue reading
6 related stories
Search tags
The company is mentioned as being subject to a securities class action lawsuit.
The company is involved in a securities class action lawsuit, although the action is specifically noted as being against Pentwater Capital Management LP.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
